Condition: Myocardial Infarction · Statin Adverse Reaction · HMG-CoA Reductase Inhibitor Toxicity · Sponsor: Kiyuk Chang, MD,PhD
Combination therapy of rosuvastatin 5mg and ezetimibe 10 mg showed similar achievement rate in decreasing LDL cholesterol level by 50% as single use of rosuvastatin 20 mg. This trial aims to prove non-inferiority of concomitant usage of low dose rosuvastatin and ezetimibe among patients with acute myocardial infarction who went through percutaneous coronary intervention at decreasing major adverse cardiac events compared to the efficacy of single use of high dose rosuvastatin.
This description comes directly from the study's public registry record.
Kiyuk Chang, MD,PhD · 82-10-9175-2076 · kiyuk@catholic.ac.kr
Eun Ho Choo, MD · 82-10-8500-4569 · cmcchu@catholic.ac.kr
Always discuss trial participation with your own doctor first.
| Bucheon St.Mary Hospital | Bucheon-si, Gyeonggido, South Korea | Recruiting |
| St.Vincent's Hospital | Suwon, Gyeonggido, South Korea | Recruiting |
| Uijeongbu St.Mary's Hospital | Uijeongbu-si, Gyeonggido, South Korea | Recruiting |
| Daejeon St.Mary's Hospital | Daejeon, South Korea | Recruiting |
| Incheon St.Mary's Hospital | Incheon, South Korea | Recruiting |
| Seoul St.Mary's Hospital | Seoul, South Korea | Recruiting |
| Yeouido St.Mary Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04499859